IP Library Granted Patent US 9,694,077
Granted Patent B2
US 9,694,077 · App. 14/508,805 · Granted Jul 4, 2017

Lipid compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,694,077
App. No.
14/508,805
Granted
Jul 4, 2017
Kind
B2
Abstract

Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).

Claims (18)

1. A composition, the composition comprising a sterol; a neutral lipid; a PEG or a PEG-modified lipid; and a lipid of formula (III), (IV) or a mixture thereof,

wherein,

each R is independently

R 1 is H;

R 2 , for each occurrence, is independently, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl; each of which is optionally substituted with one or more substituent; and

Y is O.

2. The composition of claim 1 , wherein R, for at least 3 occurrences, is

3. The composition of claim 1 , wherein R 2 is alkyl, alkenyl, or alkynyl.

4. The composition of claim 1 , wherein R for at least 3 occurrences is

5. The composition of claim 1 , comprising a compound of formula (V)

6. The composition of claim 1 , comprising a compound of formula (VI)

7. The composition of claim 1 , wherein the sterol is cholesterol.

8. The composition of claim 1 , wherein the composition comprises about 50% of the compound of formula (III), or (IV), or mixture thereof, about 38.5% of the sterol, and about 1.5% of the PEG or PEG-modified lipid, and about 10% of the neutral lipid.

9. The composition of claim 1 , further comprising a targeting lipid comprising N-acetyl galactosamine as a targeting moiety.

10. The composition of claim 1 , wherein the composition is an association complex.

11. The composition of claim 1 , wherein the composition is a liposome.

12. The composition of claim 1 , further comprising a nucleic acid agent.

13. The composition of claim 1 , further comprising at least one apolipoprotein.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Jul 27, 2018
From: PROTIVA BIOTHERAPEUTICS INC.; ARBUTUS BIOPHARMA CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 046640/0764 →
CHANGE OF NAME Recorded Nov 4, 2016
From: TEKMIRA PHARMACEUTICALS CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 040232/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2014
From: ALNYLAM PHARMACEUTICALS, INC.
To: TEKMIRA PHARMACEUTICALS CORPORATION
Reel/Frame 034397/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2014
From: MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; JAYARAMAN, MUTHUSAMY; BUTLER, DAVID; JUNG, MICHAEL E.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 034397/0744 →